Big pharma was not immune to the sell-off of shares that has spread to markets globally after hitting Wall Street on Monday.
The cause for the Dow Jones losses is believed to be fears that US interest rates might rise more quickly than expected to tackle inflation resulting from strong wage growth.
Looking at closing US prices on Monday, The Street noted that some pharma and biotech stocks outpaced the big declines in the broader stock market. The Dow ended the day down 1,175.21 points, or 4.6%. The broader S&P 500 finished 4.1%, or 113.19 points, lower.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze